Marwa Sallam

Prof. Dr. Marwa Sallam

Faculty of Pharmacy - Alexandria University, Alexandria, Al Iskandarīyah, Egypt
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
MZMakhloufi Zoulikha
Makhloufi Zoulikha
QXQingqing Xiao
Qingqing Xiao
GBGeorge Frimpong Boafo
George Frimpong Boafo
MSMarwa Sallam
Marwa Sallam
ZCZhongjian Chen
Zhongjian Chen
Wei HeWei He
Wei He
The use of small interfering RNAs (siRNAs) has been under investigation for the treatment of several unmet medical needs, including acute lung injury/acute respiratory distress syndrome (ALI/ARDS) wherein siRNA may be implemented to modify the expression of pro-inflammatory cytokines and chemokines at the mRNA level. The clear anatomy, accessibility, and relatively low enzyme activity make the lung a good target for local siRNA therapy. However, the clinical translation of siRNA is hampered by the inefficient delivery of siRNA therapeutics to the target cells due to the properties of naked siRNA. Thus, this review will focus on the various delivery systems that can be used and the different barriers that need to be surmounted for the development of stable inhalable siRNA formulations for human use before siRNA therapeutics for ALI/ARDS become available in the clinic.

29 April 2021 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
XWXiaochun Wang
Xiaochun Wang
MSMohammad Imran Shair
Mohammad Imran Shair
LFLifang Fan
Lifang Fan
ZZZongmin Zhao
Zongmin Zhao
MNMd Nurunnabi
Md Nurunnabi
Wei HeWei He
Wei He
Invasive fungal infections (IFIs) represent a growing public concern for clinicians to manage in many medical settings, with substantial associated morbidities and mortalities. Among many current therapeutic options for the treatment of IFIs, amphotericin B (AmB) is the most frequently used drug. AmB is considered as a first-line drug in the clinic that has strong antifungal activity and less resistance. In this review, we summarized the most promising research efforts on nanocarriers for AmB delivery and highlighted their efficacy and safety for treating IFIs. We have also discussed the mechanism of actions of AmB, rationale for treating IFIs, and recent advances in formulating AmB for clinical use. Finally, this review discusses some practical considerations and provides recommendations for future studies in applying AmB for combating IFIs.

1 January 2018 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
MGMai Mahmoud Gabr
Mai Mahmoud Gabr
SMSana Mohamed Mortada
Sana Mohamed Mortada
MSMarwa Sallam
Marwa Sallam

1 March 2021 in Bioengineering & Translational Medicine
Verified
Journal Article
Open access
PDF file
MSMarwa Sallam
Marwa Sallam
SPSupriya Prakash
Supriya Prakash
NKNinad Kumbhojkar
Ninad Kumbhojkar
WSWyatt Shields
Wyatt Shields
SMSamir Mitragotri
Samir Mitragotri
A growing variety of biological macromolecules are in development for use as active ingredients in topical therapies and vaccines. Dermal delivery of biomacromolecules offers several advantages compared to other delivery methods, including improved targetability, reduced systemic toxicity, and decreased degradation of drugs. However, this route of delivery is hampered by the barrier function of the skin. Recently, a large body of research has been directed toward improving the delivery of macromolecules to the skin, ranging from nucleic acids (NAs) to antigens, using noninvasive means. In this review, we discuss the latest formulation‐based efforts to deliver antigens and NAs for vaccination and treatment of skin diseases. We provide a perspective of their advantages, limitations, and potential for clinical translation. The delivery platforms discussed in this review may provide formulation scientists and clinicians with a better vision of the alternatives for dermal delivery of biomacromolecules, which may facilitate the development of new patient‐friendly prophylactic and therapeutic medicines.

15 July 2021 in Nanomedicine
Verified
Journal Article
Closed access
AKAsmaa Khafaga
Asmaa Khafaga
Rehab ShammaRehab Shamma
Rehab Shamma
AAAhmed Abdeen
Ahmed Abdeen
ABAbdelmonem M Barakat
Abdelmonem M Barakat
Ahmed E. NoreldinAhmed E. Noreldin
Ahmed E. Noreldin
MSMarwa Sallam
Marwa Sallam
While cancer remains a significant global health problem, advances in cancer biology, deep understanding of its underlaying mechanism and identification of specific molecular targets allowed the de...

8 November 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MSMai Salah
Mai Salah
MSMarwa Sallam
Marwa Sallam
MAMona A. Abdelmoneem
Mona A. Abdelmoneem
MTMohamed . Teleb
Mohamed . Teleb
KEKadria A. Elkhodairy
Kadria A. Elkhodairy
Sherine KhattabSherine Khattab
Sherine Khattab
While breast cancer remains a global health concern, the elaboration of rationally designed drug combinations coupled with advanced biocompatible delivery systems offers new promising treatment venues. Herein, we repurposed rosuvastatin (RST) based on its selective tumor apoptotic effect and combined it with the antimetabolite pemetrexed (PMT) and the tumor-sensitizing polyphenol honokiol (HK). This synergistic three-drug combination was incorporated into protein polysaccharide nanohybrids fabricated by utilizing sodium alginate (ALG) and lactoferrin (LF), inspired by the stealth property of the former and the cancer cell targeting capability of the latter. ALG was conjugated to PMT and then coupled with LF which was conjugated to RST, forming core shell nanohybrids into which HK was physically loaded, followed by cross linking using genipin. The crosslinked HK-loaded PMT–ALG/LF–RST nanohybrids exhibited a fair drug loading of 7.86, 5.24 and 6.11% for RST, PMT and HK, respectively. It demonstrated an eight-fold decrease in the IC50 compared to the free drug combination, in addition to showing an enhanced cellular uptake by MCF-7 cells. The in vivo antitumor efficacy in a breast cancer-bearing mouse model confirmed the superiority of the triple cocktail-loaded nanohybrids. Conclusively, our rationally designed triple drug-loaded protein/polysaccharide nanohybrids offer a promising, biocompatible approach for an effective breast tumor suppression.